Tong L, Pav S, White D M, Rogers S, Crane K M, Cywin C L, Brown M L, Pargellis C A
Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut 06877, USA.
Nat Struct Biol. 1997 Apr;4(4):311-6. doi: 10.1038/nsb0497-311.
The crystal structure of human p38 mitogen-activated protein (MAP) kinase in complex with a potent and highly specific pyridinyl-imidazole inhibitor has been determined at 2.0 A resolution. The structure of the kinase, which is in its unphosphorylated state, is similar to that of the closely-related ERK2. The inhibitor molecule is bound in the ATP pocket. A hydrogen bond is made between the pyridyl nitrogen of the inhibitor and the main chain amido nitrogen of residue 109, analogous to the interaction from the N1 atom of ATP. The crystal structure provides possible explanations for the specificity of this class of inhibitors. Other protein kinase inhibitors may achieve their specificity through a similar mechanism. The structure also reveals a possible second binding site for this inhibitor, with currently unknown function.
已在2.0埃分辨率下确定了与一种强效且高度特异性的吡啶基咪唑抑制剂复合的人p38丝裂原活化蛋白(MAP)激酶的晶体结构。处于未磷酸化状态的该激酶结构与密切相关的ERK2相似。抑制剂分子结合在ATP口袋中。抑制剂的吡啶基氮与残基109的主链酰胺氮之间形成氢键,类似于ATP的N1原子的相互作用。该晶体结构为这类抑制剂的特异性提供了可能的解释。其他蛋白激酶抑制剂可能通过类似机制实现其特异性。该结构还揭示了该抑制剂可能的第二个结合位点,其功能目前未知。